Navigation Links
MD Biosciences Publishes the Characterization of a Porcine Model of Post-operative Or Incisional Pain in the European Journal of Pain
Date:9/25/2013

St Paul, MN (PRWEB) September 25, 2013

MD Biosciences article "Characterization of a porcine model of post-operative pain" is published in the September 2013 issue of European Journal of Pain. Dr Sigal Meilin, lead neuroscientist and research director at MD Biosciences along with colleagues developed and published a large in vivo model of post-operative pain (POP) that provides greater translational relevance for the evaluation of local treatments of POP compared with existing rodent models of incisional pain.

The management of acute pain related to surgical intervention, termed post-operative pain, continues to be a major healthcare challenge. Historically the rodent has been the model of choice for developing new analgesic treatments in the study of POP. One of the major disadvantages of the rodent model is its limited use in assessing topical and localized treatments. The anatomy of the rodent skin is also significantly different from human skin and healing occurs primarily by wound contraction rather than re-epithelialization. Porcine skin on the other hand has a higher degree of homology to human skin and heals by epidermal cell migration. There is also a considerable correlation between contracile, metabolic and morphological features in skeletal muscle of humans and pigs. The pigskin is also tightly attached to the muscle and subcutaneous tissue as in humans.

We have developed a model of post-operative pain utilizing full-skin incision or full skin and muscle incision and retraction (SIMR). We propose that this model provides greater translational relevance for local treatments compared to rodent models and enables three important parameters to be assessed in parallel:

  •     Nociceptive sensitivity
  •     Spontaneous behavior
  •     Wound healing and inflammation

MD Biosciences research group is actively involved in developing approaches, methods and models that bring greater translational relevance to the clinical situation. With greater than 90% failure rate in the clinical trial phase of drug development, more relevant models are needed that provide greater translation to the clinic. More information about the preclinical models of pain offered at MD Biosciences or access the European Journal of Pain article can be found on MD Biosciences website.

About MD Biosciences
MD Biosciences is a leading preclinical research group and contract research organization (CRO) working with biopharmaceutical and medical device companies in an effort towards progressing discovery and development programs to clinical stages. We are deeply focused on inflammatory, neurodegenerative/CNS, pain, dermal, metabolic and cardiovascular conditions with a particular emphasis on the interplay between the immune, nervous and cardiovascular systems and the conditions that arise in the cross talk between them. We bring decisive value to preclinical programs with the extensive experience gained over many years of handling different compound classes through all administration routes aimed at numerous therapeutic indications.

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read the full story at http://www.prweb.com/releases/2013Sept/preclinicalPOPmodel/prweb11158440.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
2. SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
3. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
4. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
5. Sangamo BioSciences Proposes Public Offering Of Common Stock
6. Rancho BioSciences Partners with OmicSoft for Manual Data Curation
7. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
8. Sanguine BioSciences Signs Agreements with More than 200 Partners to Enable Efficient Personalized Medicine Research
9. Rancho BioSciences Launches Rancho tranSMART Hosted for Clinical and Genomic Data Storage and Analysis
10. Former Life Technologies and BD Biosciences Executive John L. "Kip" Miller Joins Solulinks Board of Directors
11. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... , ... DrugDev believes the only way to achieve real change ... three tenets were on display at the 2nd Annual DrugDev User Summit (hosted by ... and site organizations to discuss innovation and the future of clinical research. , ...
(Date:12/2/2016)... ... December 02, 2016 , ... Robots will storm the Prudential Center in Boston, ... The event, which is held on the United Nations International Day of Persons with ... into the workplace. Suitable Technologies is partnering with NTI to showcase how technology can ...
(Date:12/2/2016)... leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI HIV ... http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton Health ... Self Test to 350 pharmacy representatives in Nairobi and Mombasa, ...
(Date:11/30/2016)... , November 30, 2016 ... a few players hold a dominant share in the ... River Laboratories International, Inc., and Merck KGaA, held a ... 2015. Transparency Market Research observes that these companies are ... on development products that are do not require rabbit ...
Breaking Biology Technology:
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  higi ... a new partnership initiative targeting national brands, industry ... and reward their respective audiences for taking steps ... Since its inception in 2012, higi has built ... US, impacting over 38 million people who have ...
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/17/2016)... Nov. 17, 2016 Global Market Watch: ... (Disease-Based Banks, Population-Based Banks and Academics) market is to witness ... Private Biobanks shows the highest Compounded Annual Growth Rate (CAGR) ... region during the analysis period 2014-2020. North America ... 9.95% followed by Europe at 9.56% ...
Breaking Biology News(10 mins):